How Will Adoptive Cell Therapy Crack Solid Tumours? – This was the provocative question raised by the title of Dr Malcolm Brenner’s keynote lecture at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium held last week in San Francisco, ”Adoptive T cell Therapy: Target Solid Tumors by CARs or TCRs?”

Malcolm K Brenner, MD PhD is the Director of the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas.

ASCO have just named CAR-T cell immunotherapy as its “2018 Cancer Advance of the Year” so it’s timely to take a look at where we are in the adoptive cell therapy field and where it may be going?

We’ve been writing about adoptive cell therapies (ACT) such as CAR T cell therapy since 2011.  Indeed, I vividly recall one of my early interviews about it at ASH 2013 (See post: Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens)”.

In recent years, CAR T cell therapy has made tremendous progress in hematologic malignancies, gaining FDA approval last year in relapsed/refratory paediatric ALL and non-Hodgkin lymphoma (NHL). We have not seen the same efficacy in solid tumours as yet, and this remains one of the key challenges in the field today.

In this post, we take a look at the perspectives Dr Brenner offered in his keynote lecture at ASCO-SITC and the potential impact they may have on the landscape.

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by